他米巴罗汀药理学研究进展  

Pharmacological Research of tamibarotene

作　　者：杨立平[1] 

机构地区：[1]湖南省肿瘤医院,湖南长沙410013

出　　处：《中华临床医学杂志》2008年第7期57-60,共4页Chinese Journal of Clinical Practical Medicine

摘　　要：本文对他米巴罗汀的药理学进行综述。他米巴罗汀是一个新的维甲酸受体α（RARα）促进剂，在体外可诱导急性早幼粒细胞性白血病基因（PML）分化和成熟，抑制PML增殖。在临床试验中，他米巴罗汀显示了明显的抗肿瘤活性和较好的耐受性。Pharmacologic and pharmacodynamics of tamibarotene were reviewed in this paper. Tamibarotene is a new RARer agonist, and it successfully induces PML differentiation and maturation in vitro, deterring PML proliferation. In invivo studies, tamibarotene demonstrates antitumor activity and good tolerability.

关 键 词：他米巴罗汀 急性早幼粒细胞性白血病 药理学 

分 类 号：R969[医药卫生—药理学]